Results 111 to 120 of about 20,043 (161)

Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion. [PDF]

J Antimicrob Chemother
Nakalema S, Namuddu D, Kyohairwe I, Nakatudde I, Malaba T, Myer L, Colbers A, Reynolds H, Read J, Lamorde M, Khoo S, Waitt C.   +11 more
europepmc   +1 more source

Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review. [PDF]

Front Pharmacol
Spanakis M, Alexakis K, Ioannou P.
europepmc   +1 more source

Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity. [PDF]

Front Med (Lausanne)
Bailey B, Rudd Zhong Manis J, Seth G, Rajpurohit S, Oxenrider A, Martin PM, Jadeja RN, Thounaojam MC.   +7 more
europepmc   +1 more source

R263K-associated dolutegravir resistance on tenofovir, lamivudine and dolutegravir: Implications for earlier genotyping and regimen optimisation. [PDF]

S Afr J Infect Dis
Naidoo S.
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

Impact of Dihydrocapsaicin on the Metabolism of Efavirenz In Vitro and In Vivo. [PDF]

Pharmacol Res Perspect
Wang B, Ma X, Wang X, Chen Y, Zhou Q, Al Mamun A, Wang G, Wang S, Ma X.   +8 more
europepmc   +1 more source

HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. [PDF]

J Antimicrob Chemother
Schönenberger CM, Haenggi K, Ringera IK, Luoga E, Bresser M, Mothobi B, Mokhele K, Sando D, Molatelle M, Thahane L, Mnzava D, Ndege R, Hlasoa MM, Kayembe BP, Muhairwe J, Glass TR, Klimkait T, Weisser M, Labhardt ND, Tschumi N, Brown JA.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efavirenz: a review

Expert Opinion on Pharmacotherapy, 2007
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection.
Ferdinand Wnm Wit, Joep M A Lange
exaly   +3 more sources

Efavirenz

Drugs, 2012
Stuart Noble, Julie C Adkins, S Noble
exaly   +3 more sources